Tags

Type your tag names separated by a space and hit enter

Subacute cutaneous lupus erythematosus exacerbated or induced by chemotherapy.
Arch Dermatol. 2010 Oct; 146(10):1113-6.AD

Abstract

BACKGROUND

Subacute cutaneous lupus erythematosus (SCLE), characterized by nonscarring, photodistributed, annular or papulosquamous plaques, is occasionally induced by medication. It has been strongly associated with antihypertensive medications and terbinafine hydrochloride.

OBSERVATION

We describe 3 women with breast cancer who developed SCLE-like eruptions after being administered doxorubicin hydrochloride and cyclophosphamide. Biopsy specimens of all 3 patients demonstrated an interface dermatitis. Treatment consisted of topical and/or systemic corticosteroids, photoprotection, and switching the chemotherapeutic regimens.

CONCLUSIONS

Based on clinicopathologic correlation and timing of chemotherapy exposure, the patients were believed to have drug-induced SCLE. Although cutaneous eruption, pruritus, and photosensitivity are known adverse effects of doxorubicin, to our knowledge there has been only 1 previously reported case of doxorubicin-induced SCLE.

Links

Publisher Full Text (DOI)

Authors+Show Affiliations

Funke AA
Division of Dermatology, Department of Medicine, University of Louisville School of Medicine, Louisville, Kentucky, USA. alisa.funke@ucdenver.edu
Kulp-Shorten CL
No affiliation info available
Callen JP
No affiliation info available

MeSH

AdultAgedAntineoplastic AgentsCyclophosphamideDoxorubicinFemaleHumansLupus Erythematosus, Cutaneous

Pub Type(s)

Case Reports
Journal Article

Language

eng

PubMed ID

20956642

Citation

Funke, Alisa A., et al. "Subacute Cutaneous Lupus Erythematosus Exacerbated or Induced By Chemotherapy." Archives of Dermatology, vol. 146, no. 10, 2010, pp. 1113-6.
Funke AA, Kulp-Shorten CL, Callen JP. Subacute cutaneous lupus erythematosus exacerbated or induced by chemotherapy. Arch Dermatol. 2010;146(10):1113-6.
Funke, A. A., Kulp-Shorten, C. L., & Callen, J. P. (2010). Subacute cutaneous lupus erythematosus exacerbated or induced by chemotherapy. Archives of Dermatology, 146(10), 1113-6. https://doi.org/10.1001/archdermatol.2010.258
Funke AA, Kulp-Shorten CL, Callen JP. Subacute Cutaneous Lupus Erythematosus Exacerbated or Induced By Chemotherapy. Arch Dermatol. 2010;146(10):1113-6. PubMed PMID: 20956642.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Subacute cutaneous lupus erythematosus exacerbated or induced by chemotherapy. AU - Funke,Alisa A, AU - Kulp-Shorten,Carol L, AU - Callen,Jeffrey P, PY - 2010/10/20/entrez PY - 2010/10/20/pubmed PY - 2010/11/3/medline SP - 1113 EP - 6 JF - Archives of dermatology JO - Arch Dermatol VL - 146 IS - 10 N2 - BACKGROUND: Subacute cutaneous lupus erythematosus (SCLE), characterized by nonscarring, photodistributed, annular or papulosquamous plaques, is occasionally induced by medication. It has been strongly associated with antihypertensive medications and terbinafine hydrochloride. OBSERVATION: We describe 3 women with breast cancer who developed SCLE-like eruptions after being administered doxorubicin hydrochloride and cyclophosphamide. Biopsy specimens of all 3 patients demonstrated an interface dermatitis. Treatment consisted of topical and/or systemic corticosteroids, photoprotection, and switching the chemotherapeutic regimens. CONCLUSIONS: Based on clinicopathologic correlation and timing of chemotherapy exposure, the patients were believed to have drug-induced SCLE. Although cutaneous eruption, pruritus, and photosensitivity are known adverse effects of doxorubicin, to our knowledge there has been only 1 previously reported case of doxorubicin-induced SCLE. SN - 1538-3652 UR - https://www.unboundmedicine.com/medline/citation/20956642/Subacute_cutaneous_lupus_erythematosus_exacerbated_or_induced_by_chemotherapy_ DB - PRIME DP - Unbound Medicine ER -